SCHEMBL4756500

SCHEMBL4756500

Cc1ccc(N2CCCC(C3OCCN(C(=O)O)C3C)C2)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.40
ALDH1A1 P00352 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 2/20 0.40
CCR1 P32246 1/20 0.40
CCR2 P41597 1/20 0.40
ACACB O00763 1/20 0.37
MAPT P10636 7/20 0.36
RAB9A P51151 3/20 0.36
GAA P10253 2/20 0.36
NPC1 O15118 3/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
BLM P54132 1/20 0.35
TSHR P16473 3/20 0.35
TP53 P04637 1/20 0.35
HTT P42858 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4706540 0.91 KDM4E (0.39) HPGDALDH1A1SMN1; SMN2ACACBMAPT
SCHEMBL4823139 0.79 CCR1 (0.46) HPGDALDH1A1SMN1; SMN2LMNACCR1
SCHEMBL5661256 0.76 CCR1 (0.41) HPGDALDH1A1SMN1; SMN2LMNACCR1
SCHEMBL15759157 0.70 CCR1 (0.44) HPGDALDH1A1SMN1; SMN2LMNACCR1
SCHEMBL4707178 0.70 LMNA (0.46) HPGDALDH1A1SMN1; SMN2LMNACCR1
SCHEMBL13419316 0.69 PBK (0.46) HPGDALDH1A1SMN1; SMN2LMNACCR1
SCHEMBL4756496 0.69 MAPT (0.42) HPGDALDH1A1SMN1; SMN2LMNAACACB
SCHEMBL5659856 0.68 HTT (0.39) HPGDALDH1A1SMN1; SMN2ACACBMAPT
SCHEMBL12175957 0.67 ALDH1A1 (0.56) HPGDALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL27664371 0.67 MAPT (0.54) HPGDALDH1A1SMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979318-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2008-10-15 EP claimed
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US claimed
WO-2007089683-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2007-08-09 WO claimed
EP-1979318-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2008-10-15 EP disclosed
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US disclosed
WO-2007089683-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197530-A1 Amido compounds and their use as pharmaceuticals HSD11B1, HSD17B11, CYP11B1 HPGD 50/4885ALDH1A1 165/4885SMN1; SMN2 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.